

AD\_\_\_\_\_

AWARD NUMBER: W81XWH-04-1-0884

TITLE: Radioimmunotherapy (RIT) Dose-Escalation Studies in Prostate Cancer  
Using Anti-PSMA Antibody 177Lu-J591: RIT Alone and RIT in Combination with  
Docetaxel

PRINCIPAL INVESTIGATOR: Shankar Vallabhajosula, Ph.D.

CONTRACTING ORGANIZATION: Cornell University  
New York, NY 10021

REPORT DATE: October 2008

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
1. REPORT DATE 1 Oct 2009		2. REPORT TYPE Annual		3. DATES COVERED 15 Sep 2007 – 14 Sep 2008	
4. TITLE AND SUBTITLE  Radioimmunotherapy (RIT) Dose-Escalation Studies in Prostate Cancer Using Anti-PSMA Antibody 177Lu-J591: RIT Alone and RIT in Combination with Docetaxel				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0884	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)  Shankar Vallabhajosula, Ph.D.  E-Mail: svallabh@med.cornell.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  Cornell University New York, NY 10021				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT In the fall of 2007, we started the Phase I dose escalation studies with 177Lu-DOTA-huJ591 monoclonal antibodies (mAb) using dose fractionation regimen. In patients with PCa and who have recurrent and/or metastatic disease, 177Lu dose (20-40 mCi/m2) was escalated in 5 different dose levels (3-6 patients at each dose level). So far we have recruited 17 patients in 5 groups. At each dose level, the patients received two doses of 177Lu-J591 mab, 2 weeks apart. The dose of huJ591 MAb remained fixed at 20 mg/dose. We hope to complete this first trial by June 2009 and start the combination therapy protocol almost immediately. The combination therapy protocol was approved by our IRB and was submitted to DOD HSRRB for review and approval. We started recruitment of subjects into the combination therapy protocol. Our goal is to complete the study in by September 2010. The revised SOW is attached.					
15. SUBJECT TERMS Radioimmunotherapy, Prostate cancer, 177Lu-DOTA-J591 antibody, Dose-Fractionation					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT  UU	18. NUMBER OF PAGES  20	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

## Table of Contents

	<u>Page</u>
<b>Introduction .....</b>	<b>1</b>
<b>Body.....</b>	<b>2</b>
<b>Key Research Accomplishments.....</b>	<b>4</b>
<b>Reportable Outcomes.....</b>	<b>5</b>
<b>Conclusion.....</b>	<b>10</b>
<b>References.....</b>	<b>11</b>
<b>Appendices.....</b>	<b>13</b>

## Introduction

We still lack a systemic treatment that clearly demonstrates improved survival in patients with disseminated hormone resistant prostate cancer (PC). Targeted radioimmunotherapy (RIT) utilizing radiolabeled monoclonal antibodies (mAbs) directed to cancer-related cell surface antigens has been clinically validated with the FDA approval of  $^{90}\text{Y}$  and  $^{131}\text{I}$  labeled anti-CD20 mAbs (Zevalin and Bexxar) for the treatment of lymphoma. Metastatic PC is a rational candidate for RIT since PC is radioresponsive, and typically develops as small-volume micro-metastatic sites of disease in marrow and lymph nodes that receive high levels of mAb. In PC, the most well established, prostate-restricted, cell surface antigen yet identified is prostate specific membrane antigen (PSMA). It is an ideal target for developing therapeutic agents as it is expressed by all the PCs and the expression levels progressively increase in more poorly differentiated, metastatic and hormone-refractory prostate cancers (HRPC).

**J591 is a de-immunized mAb that binds with a very high affinity to the extracellular domain of PSMA on the viable tumor cells.** In addition, the PSMA-J591 antibody complex is internalized, thereby delivering any antibody payload (radioisotope or drug) to the interior of the targeted cells. We have demonstrated radiolabeled J591 sensitively and specifically targets sites of metastatic PC in both bone and soft tissue. In a Phase I studies, we have determined that  $^{90}\text{Y}$ -J591 ( $17.5 \text{ mCi/m}^2$ ) and  $^{177}\text{Lu}$ -J591 ( $70 \text{ mCi/m}^2$ ) mAbs either decrease or stabilize serum PSA levels. We have selected  $^{177}\text{Lu}$ -J591 as an agent of choice for further studies.  $^{90}\text{Y}$  may be appropriate for larger tumors while  $^{131}\text{I}$  may be more cytotoxic for smaller, micro-metastatic lesions typically seen in HRPC.  $^{177}\text{Lu}$  behaves chemically like  $^{90}\text{Y}$  and is stable in vivo.  $^{177}\text{Lu}$  has low energy  $\beta$ - particles and suitable  $\gamma$  photons for dosimetric studies. Thus it has advantages of both  $^{90}\text{Y}$  and  $^{131}\text{I}$ , but none of their disadvantages. Therefore  **$^{177}\text{Lu}$ -J591 may be an ideal agent for RIT studies of PC.** The degree of anti-tumor response following RIT depends on several variables, especially total (cumulative) radiation dose to the tumor, dose-rate and tumor radiosensitivity. Also, myelotoxicity is the dose-limiting factor in RIT. Therefore strategies are needed to optimize dosimetry to the bone marrow and tumor. Dose-fractionation is a practical strategy to decrease the dose to bone marrow while increasing the cumulative radiation dose to the tumor at an optimal dose-rate. Preclinical studies strongly support this strategy. Combined modality radioimmunotherapy (CMRIT) is another strategy designed to enhance the cascade of molecular events required for apoptotic tumor cell death resulting from the continuous low dose-rate radiation. FDA approved anti-neoplastic agent Docetaxel can cause microtubular dysfunction and as a result cells are blocked in the G2/M phase of the cell cycle, thus increasing sensitivity of cells to radiation.

Therefore, **we propose to perform two independent phase I dose-escalation studies** in patients with HRPC. The first protocol is designed to determine the cumulative MTD of  $^{177}\text{Lu}$ -J591, in a fractionated dose regimen of 2 low dose treatments given 2 weeks apart. A follow up protocol is designed to determine a safe dose of docetaxel to be given in combination with a fractionated dose regimen of  $^{177}\text{Lu}$ -J591. This research proposal thus combines several important strategies for successful RIT of PC; a very specific and high affinity anti-PSMA mAb J591, an ideal radionuclide  $^{177}\text{Lu}$  with useful  $\gamma$  and  $\beta$ - energies for imaging and therapy, **dose fractionation and CMRIT strategies (with docetaxel) to reduce myelotoxicity and to augment the anti-tumor response of RIT.** In the revised SOW attached here, we identified 4 major tasks.

## Body of Text based on SOW

### REVISED STATEMENT OF WORK (SOW) July 20, 2009

PageTask 1: Preparation of  $^{177}\text{Lu}$ -DOTA-J591 mAB for clinical studies.

Under GMP conditions, monoclonal antibody HuJ591-GS Antibody was DOTA conjugated, vialled and labeled by Immunomedics Inc. which is the current manufacturer of record for the vialled DOTA-HuJ591 antibody drug product. The manufacturer's address and telephone number are:

Immunomedics Inc.  
300 Americasn Road  
Morris Plains, NJ 07950  
Phone: 973-605-8200

The drug product consists of DOTA-HuJ591 antibody in 0.3 M ammonium acetate, pH 7.2, in 2 mL thermoplastic vials with gray butyl rubber stoppers and blue flip-off crimp seal closures. The nominal concentration is 8.0 mg/mL and the nominal fill volume is 1.3 mL. There are no other excipients added.

$^{177}\text{Lu}$ -Labeling of DOTA-J591: 3 batches of the above lot of DOTA-J591 were labeled with  $^{177}\text{Lu}$  to a specific activity of 10-20 mCi/mg. All the QC tests indicated that the material is suitable for clinical studies.

**The above process was started around October and final tests were completed by March 2007.**

Task 2: Obtain IRB approval of the Phase I dose escalation protocol using  $^{177}\text{Lu}$ -J591 in a fractionated dose regimen

- After 16 months of interaction with HSRRB at DOD, the protocol was finally approved in May 2006. Subsequently, the protocol (modified by Cornell IRB and DOD HSRRB) was submitted to FDA for permission to start the clinical trial under an IND.
- In August 2006, the physician who is responsible for recruiting the patients and who is the PI on the institutional protocol left Cornell medical center. We subsequently replaced the physician and resubmitted the protocol for IRB approval and FDA approval.
- Finally in January 2007, we received the approval from FDA following minor modifications to the protocol as suggested by FDA.
- The revised protocol was resubmitted to Cornell IRB and then finally to HSRRB at DOD (in January 2007)
- After several communications, we were just informed that the protocol is finally approved. We are still waiting for the formal letter of approval from DOD.
- **The protocol was finally approved by HSRRB in July 2007 and clinical studies started**

Task 3:            Phase I clinical trial with  $^{177}\text{Lu}$ -J591 Dose fractionation regimen

- The Task 3 was started in the fall of 2007. We have recruited 16 patients in this protocol and we expect to complete this protocol over the next 6-9 months. We reported the preliminary results of dose fractionation protocol in a major conference.
- As of July 2009, we have studied 5 groups of subjects who received 2 doses (2 weeks apart) with 20, 25, 30, 35 mCi/m<sup>2</sup>  $^{177}\text{Lu}$ -J591. The patients in the last group are under follow-up. We have not yet received the MTD.
- Preliminary data from this trial was presented at the Genitourinary Cancer symposium in 2009.
- In the month of August 09, we plan to start the next group with 45 mCi/m<sup>2</sup> and recruit 3 subjects over a period of 6-8 weeks.

Task 4:            Phase 1 Clinical trial with combination therapy ( $^{177}\text{Lu}$ -J591 and Docetaxel).

- The design of Phase 1 protocol of combination therapy was finalized. The protocol was formally submitted to IRB. We expect the IRB approval process will be completed in less than 2 weeks.
- Dr. Scott Tagawa (PI of the clinical protocol) submitted the protocol to DOD HSSRB for review. The goal is to study 5 groups starting with 20 mCi/m<sup>2</sup>. The patient would first receive 4 weeks of Docetaxel and then on week 5 and 7 would also receive  $^{177}\text{Lu}$ -J591 dose.
- As of July 09, two patients were recruited into the trial and received the treatment dose.
- The plan is to recruit 3 patients in each group every 3 months.
- We hope to complete the recruitment and follow-up by October 2010. The final data analysis will be completed after the patient recruitment is finished.

The final data analysis will be completed after the patient recruitment is finished.

### **Key Research Accomplishments**

- Preparation of new lot of DOTA-J591 and optimization of  $^{177}\text{Lu}$  labeling.
- Obtaining IRB approvals following repeated review of protocol by Cornell IRB, HSRRB and FDA
- Obtaining HSSRB approval for the trial
- Recruited the 16 subjects in Groups 1-4 of the first phase I clinical study evaluating the dose fractionation.
- Submission of combination therapy ( $^{177}\text{Lu}$ -J591 + Docetaxel) protocol to Cornell IRB

## Reportable Outcomes

### Reportable Outcomes

**Phase I trial of fractionated-dose  $^{177}\text{Lu}$ lutetium radiolabeled antiprostata-specific membrane antigen (PSMA) monoclonal antibody J591 ( $^{177}\text{Lu}$ -J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC).**

**Sub-category:**

Early/Localized disease, Locally Advanced/Recurrent/Advanced disease, and Biology

**Category:**

Genitourinary Cancers

**Meeting:**

2009 Genitourinary Cancers Symposium

**Abstract No:**

172

**Author(s):**

**S. T. Tagawa, S. Vallabhajosula**, S. J. Goldsmith, K. Petrillo, D. Matulich, J. Kaplan, N. H. Bander, D. M. Nanus; Weill Cornell Medical College, New York, NY

**Abstract:**

**Introduction:** A phase II trial of single-dose  $^{177}\text{Lu}$ -J591 radioimmunotherapy (RIT) in pts with metCRPC confirmed previously described anti-tumor activity, excellent targeting of met sites, and acceptable toxicity with an apparent dose-response relationship [Tagawa et al, ASCO 2008]. Dose fractionation of RIT may decrease toxicity (myelosuppression) while maintaining or increasing efficacy [DeNardo et al, 2002].

**Methods:** In this phase I study, cohorts of 3-6 pts with progressive metCRPC receive 2 fractionated doses of  $^{177}\text{Lu}$ -J591 2 weeks apart: Cohort 1 (20 mCi/m<sup>2</sup> x2), dose escalation 5 mCi/m<sup>2</sup> per dose per cohort. The primary endpoint is to determine dose limiting toxicity (DLT) and the cumulative maximum tolerated dose (MTD) of fractionated  $^{177}\text{Lu}$ -J591 RIT with pharmacokinetics and dosimetry and secondary endpoints of efficacy. DLT was defined as Gr >3 hematologic toxicity or Gr >2 non-hematologic toxicity.

**Results:** Median age of the 11 treated pts is 78 (range 63-86), median baseline PSA 49.5 (23.7-265.9), 91% with ECOG PS 1, 9% ECOG 2. 82% had bone mets, 45% lymph node mets, and 36% extra-osseous visceral mets (lung). All pts had progressed after 1-3 hormonal therapies and 36% progressed on 1-4 lines of chemotherapy including docetaxel. No DLT's have been seen. 2 pts experienced reversible Gr 3 neutropenia and 1 Gr 3 thrombocytopenia; no growth factors or transfusions were needed. There was no Gr >1 non-hematologic toxicity. Overall, 5 of 11 pts experienced a PSA decline. Excluding the lowest dose-level, 63% experienced a PSA decline (with median time to progression of 20 weeks), 2 with >30% decline, 1 with >50% decline. Excellent targeting of known sites of PC metastases was seen in the majority of pts.

**Conclusions:** Fractionated dose  $^{177}\text{Lu}$ -J591 is well tolerated, with reversible myelosuppression, demonstrating anti-tumor activity in pts with progressive metCRPC. The MTD has not yet been reached and enrollment continues on cohort 4 (35 mCi/m<sup>2</sup> x2) with plans to proceed to combination therapy with docetaxel.



## **1. Preparation of DOTA-J591 by Immunomedics Inc**

Under GMP conditions, HuJ591-GS monoclonal Antibody was DOTA conjugated, vialled and labeled by Immunomedics Inc. which is the current manufacturer of record for the vialled DOTA-HuJ591 antibody drug product.

The drug product consists of DOTA-HuJ591 antibody in 0.3 M ammonium acetate, pH 7.2, in 2 mL thermoplastic vials with gray butyl rubber stoppers and blue flip-off crimp seal closures. The nominal concentration is 8.0 mg/mL and the nominal fill volume is 1.3 mL. There are no other excipients added.

Lot No: #0612012

Date of Manufacture: December 2006

Number of DOTA-J591 mAb vials: 165

Number of DOTAs/antibody: 3-4 (Tested by Immunomedics, Inc)

*The batch release documents provided by Immunomedics, Inc are included in the Appendix-A*

## **2. Acceptance testing of DOTA-J591**

Upon the receipt of DOTA-J591 mAb vials from Immunomedics, Inc. the vials were accepted for clinical use following labeling with  $^{177}\text{Lu}$  and quality control testing. 4 batches of  $^{177}\text{Lu}$ -DOTA-J591 were prepared at different specific activities (10-20 mCi/mg). The QC results are shown in Table-1.

**Table- 1: Evaluation of DOTA-J591 (lot #0612012)**

Date	Batch	Incubation Time (min)	$^{177}\text{Lu}$ -Labeling efficiency (%)	SA mCi/mg	Immuno-reactivity (%)
1/31/2007	1	15 min 30 min	94.3 100.0	10	90.6
	2	15 min 30 min 60 min	89.2 98.0 100.0	20	87.2
2/2/2007	3	15 min 30 min	70 100	5	94.1
2/22/2007	4	30 min	100	22.5	87.4
		<b>Mean <math>\pm</math> SD</b>	<b>100</b>	<b>14.3 <math>\pm</math> 8.2</b>	<b>89.8 <math>\pm</math> 3.2</b>

**Conclusion:** The results in Table -1 indicate that DOTA-J591 mAb manufactured by Immunomedics, Inc was acceptable for clinical studies. Incubation of DOTA-J591 (10mg) with  $^{177}\text{Lu}$  chloride (up to 225 mCi) will result in almost 100% labeling efficiency. The immunoreactivity was well preserved (90%). In addition to the above tests, the sterility and pyrogenicity tests have also indicated that  $^{177}\text{Lu}$ -DOTA-J591 preparation is acceptable for clinical studies.

### **3. Phase 1 dose-escalation studies with $^{177}\text{Lu}$ -DOTA-J591: Dose fractionation regimen**

In this phase I study, cohorts of 3-6 pts with progressive metastatic castrate-resistant prostate cancer (metCRP) received 2 fractionated doses of  $^{177}\text{Lu}$ -J591, 2 weeks apart: Cohort 1 was started at 20 mCi/m<sup>2</sup> x 2 doses 2 weeks apart). Subsequently each cohort dose was escalated at 5 mCi/m<sup>2</sup> per dose increment.

The primary endpoint was to determine dose limiting toxicity (DLT) and the cumulative maximum tolerated dose (MTD) of fractionated  $^{177}\text{Lu}$ -J591 RIT with pharmacokinetics and dosimetry and secondary endpoint of efficacy. DLT was defined as Grade >3 heme toxicity or Grade >2 non-heme toxicity.

#### **Inclusion Criteria** (summary)

- Histologically proven adenocarcinoma of prostate
- Radiographically evident metastatic disease
- Progression despite medical/surgical castration (testosterone < 50)
- Adequate bone marrow and organ function

#### **Exclusion Criteria** (summary)

- ECOG performance status > 2
- Prior radioisotopes (e.g. strontium, samarium)
- Bone scan with confluent lesions of axial/appendicular skeleton (superscan)
- Prior radiotherapy to > 25% of skeleton

#### **Treatment**

##### **Cohorts of 3-6 subjects**

- Cohort 1: initial dose of  $^{177}\text{Lu}$ -J591 at 20 mCi/m<sup>2</sup> IV D1, D15
- Each subsequent cohort receives escalating doses of 5 mCi/m<sup>2</sup> per dose per cohort (i.e. cumulative dose escalation of 10 mCi/m<sup>2</sup> per cohort)
- No pre-medications given

##### **Definition of Dose Limiting Toxicity (DLT)**

- Platelet count < 15,000 or need for > 3 platelet transfusion in 30 days
- Gr 4 neutropenia
- Febrile neutropenia
- Attributable Gr  $\geq$  3 non-hematologic toxicity (excluding infusion reactions)

#### **Results**

##### **Patient recruitment and dose escalation cohorts**

As of March 14<sup>th</sup> 2009, 16 patients were recruited in this protocol and received 4 dose levels; 20, 25, 30, and 35 mCi/m<sup>2</sup>; 2 doses given 2 weeks apart). The details of subject recruitment and doses received are shown in Table-2.

- Median age of the 16 treated pts is 75 (range 62-86)
- Median baseline PSA 49.8 (14.8 – 277.2)
- 6% with ECOG PS 0; 75% PS 1; 19% PS 2.
- 81% had bone mets, 56% lymph node mets, and 44% extra-osseous visceral mets (lung, liver)
- All pts had progressed after 1-3 hormonal therapies and 37% progressed on 1-4 lines of chemotherapy including docetaxel.

**Table - 2: Phase I: Lu-177 -J591 Dose Fractionation Studies**

No.	TX Date	Pt.	Dose (mCi)	BSA	mCi/ m2	mCi	SA (mCi/mg)	RCP (%)	Immuno-reactivity	Sterility	Pyrogeni city
Cohort 1											
1	8/16/07	VC	37.40	1.87	20	38.5	12.6	100	94	Pass	Pass
	8/30/07	VC	37.40	1.87	20	39.7	12	99		Pass	Pass
2	8/30/07	WE	36.80	1.84	20	38	12.0	100		Pass	Pass
	9/13/07	WE	36.80	1.84	20	38.2	7.6	99.2	90.7	Pass	Pass
3	10/4/07	SH	47.00	2.34	20	48.6	11.2	99.5	81	Pass	Pass
	10/19/07	SH	47.00	2.34	20	47.8	10.8	>99.5	83.5	Pass	Pass
Cohort 2											
4	12/6/07	NL	52.50	2.1	25	53	11.9	99.7		Pass	Pass
	12/20/07	NL	52.50	2.1	25	53.1	12.89	98.45	89.4	Pass	Pass
5	12/13/07	JJP	48.00	1.92	25	48.5	13.24	>99.5	92.6	Pass	Pass
	12/27/07	JJP	48.00	1.92	25	49.3	11.29	>99.5	97.2	Pass	Pass
6	12/19/07	JE	49.25	1.97	25	51	10.31	99.38		Pass	Pass
	1/3/08	JE	49.25	1.97	25	53	10.87	99.77	84.7	Pass	Pass
Cohort 3											
7	3/19/08	TG	54.60	1.82	30	55.7	10.26	99.81	99.3	Pass	Pass
	4/2/08	TG	54.60	1.82	30	57.4	11.925	99.68	93.7	Pass	Pass
8	3/27/08	WB	70.20	2.34	30	69.3	9.88	99.9	97.8	Pass	Pass
	4/9/08	WB	70.20	2.34	30	71.5	12.5	100		Pass	Pass
9	5/15/08	PL	57.90	1.93	30	58.3	8.45	100		Pass	Pass
	5/29/08	PL	57.90	1.93	30	58.6	9.02	100		Pass	Pass
10	6/26/08	VM	57.30	1.91	30	59.8	9.07	99.93		Pass	Pass
	7/10/08	VM	57.30	1.91	30	59.1	8.8	99.61	99	Pass	Pass
Cohort 4											
11	8/26/08	DG	66.15	1.89	35	68.8	8.45	99.22	87	Pass	Pass
	9/10/08	DG	66.15	1.89	35	65.7	9.19	100		Pass	Pass
12	11/20/08	JG	79.8	2.28	35	79.6	9.45	99.86	102.4	Pass	Pass
	12/4/08	JG	79.8	2.28	35	82.8	9.02	99.85	84.9	Pass	Pass
13	12/10/08	BF	67.55	1.93	35	70.2	8.84	99.99	81.1	Pass	Pass
	12/24/08	BF	67.55	1.93	35	69.6	11.1	100	85.3	Pass	Pass
14	1/22/09	SS	59.15	1.69	35	63	9.78	99.97	94.7	Pass	Pass
	2/5/09	SS	59.15	1.69	35	61.1	8.35	100	93.1	Pass	Pass
15	2/4/09	MG	81.2	2.32	35	83.8	10.27	100	93.3	Pass	Pass
	2/18/09	MG	81.2	2.32	35	82.4	9.29	100	81	Pass	Pass
16	2/13/09	RPE	73.5	2.1	35	71.1	9.06	100	99.8	Pass	Pass
Mean							10.3	99.7	91.2		
SD							1.5	0.4	6.7		
Patient 16 had an allergic reaction and was not treated with the second dose											

### Toxicity

(individual subject worst grade to date)

- Infusion Reactions (n = 16 evaluable)  
6 (44%) overall (5 Gr 1, 1 Gr 3). All were transient, reversible

- Thrombocytopenia (n=12 evaluable)  
Gr 0 = 17%; Gr 1-2 = 75%; Gr 3 = 8%; Gr 4 = 0%

No pts had significant bleeding or received platelet transfusions


Thrombocytopenia following  $^{177}\text{Lu}$ -J591 treatment (20-35  $\text{mCi/m}^2$ ) is shown in **Figure-1**

- Neutropenia (n=12 evaluable)  
Gr 0 = 42%; Gr 1-2 = 42%; Gr 3 = 16%; Gr 4 = 0%

No febrile neutropenia (no growth factor use)

- Transaminitis (n=12 evaluable)  
Transient Gr 1 17% (no Gr > 1)

**Figure-1: Thrombocytopenia in 4 different groups of patients following  $^{177}\text{Lu}$ -J591 treatment (20-35  $\text{mCi/m}^2$ )**



#### Preliminary Efficacy Results (n=11 evaluable)


- Any PSA decline = 45% (all evaluable pts)
- Excluding cohort 1 (20  $\text{mCi/m}^2$  x2):  
Any PSA decline = 63% (median time to progression = 20 weeks)  
2 with > 30% PSA decline (including 1 with > 50%)

### Targeting: $^{177}\text{Lu}$ -J591 Imaging studies

Following the administration of the 1<sup>st</sup> dose whole body anterior and posterior scans were obtained 3-5 times over a period of 14 days. The  $^{177}\text{Lu}$  uptake in tumor lesions was compared to the lesions identified in conventional bone scans (Figure -2).

- 11/13 evaluable scans (85%) had accurate imaging of known sites of metastatic disease.

Figure-2: Comparison of  $^{177}\text{Lu}$ -J591 imaging with standard bone scans



## CONCLUSIONS

- Fractionated  $^{177}\text{Lu}$ -J591 is well-tolerated, with reversible myelosuppression
- Successful targeting of known sites of metastatic disease occurs in the majority of patients
- PSA declines have been seen despite a potentially sub-optimal (for  $^{177}\text{Lu}$ ) pt population with bulky disease
- The MTD has not been reached, with enrollment ongoing on Cohort 5 with a cumulative dose exceeding the single dose MTD
- A phase I study in combination with docetaxel will begin enrollment in early 2009

## References

1. Smith-Jones PM, **Vallabhajosula S**, Bastidas D, Hunter C, Navarro V, Bander NH and Goldsmith SJ. Preclinical studies with <sup>131</sup>I and <sup>111</sup>In labeled monoclonal antibodies, specific for either the intracellular or extracellular domains of prostate specific membrane antigen. *J Label Comp Radiopharm* 1999; 42:suppl 1,s701-703
2. Smith-Jones PM, **Vallabhajosula S**, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH. In vitro Characterization of Radiolabeled Monoclonal Antibodies Specific for the Extracellular Domain of Prostate-specific Membrane Antigen. *Cancer Res* 2000; 60:5237-5243.
3. Smith-Jones PM, **Vallabhajosula S**, St. Omer S, Navarro V, Goldsmith SJ, Bander NH, <sup>177</sup>Lu-DOTA-HuJ591: A new Radiolabeled monoclonal antibody (MAb) for targeted therapy of prostate cancer. *J Label Comp Radiopharm* 2001;44:Suppl 1:90-92.
4. Yao D, Trabulsi EJ, Kostakoglu L, **Vallabhajosula S**, Joyce MA, Nanus DM, Milowsky M, Liu H, Goldsmith, SJ. The utility of monoclonal antibodies in the imaging of prostate cancer. *Sem Urol Onc* 2002;20:211-218.
5. Smith-Jones PM, **Vallabhajosula S**, Navarro V, et al: Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. *J Nucl Med* 44:610-7, 2003
6. Nanus D, Milowsky MI, Kostakoglu L, Smith-Jones PM, **Vallabhajosula S**, Goldsmith SJ and Bander NH: Clinical use of Monoclonal Antibody HuJ591 Therapy: Targeting Prostate Specific Membrane Antigen. *J Urol*, 2003;**170**:S84-S89.
7. Bander, NH, Trabulsi E, Kostakoglu L, Yao D, **Vallabhajosula S**, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM and Goldsmith SJ: Targeting Metastatic Prostate Cancer with Radiolabeled Monoclonal Antibody J591 in the Extracellular Domain of Prostate Specific Membrane Antigen. *J Urol*,2003;**170**:1717-1721.
8. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, **Vallabhajosula S**, and Goldsmith SJ.: Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate specific membrane antigen (PSMA). *Seminars in Oncology*,2003;**30**:667-677.
9. **Vallabhajosula S**, Kothari PA, Konishi S, Hamacher KA, Goldsmith SJ, Bander NH. Radiolabeled J591 antibody specific to prostate specific membrane antigen (PSMA): comparison of Indium-111, Yttrium-90 and Lutetium-177. *J Label Radiopharma Compunds* 2003;
10. **Vallabhajosula S**, Smith-Jones PM, Navarro V, Goldsmith SJ and Bander NH: Radioimmunotherapy Of Prostate Cancer In Human Xenografts Using Monoclonal Antibodies Specific To Prostate Specific Membrane Antigen (PSMA): Studies In Nude Mice. *The Prostate* 2004; 58:145-155.
11. Milowsky MI, Nanus DM, Kostakoglu L, **Vallabhajosula S**, Goldsmith SJ, Bander NH. Phase I Trial of <sup>90</sup>Y-Labeled Anti-PSMA Monoclonal Antibody J591 For Androgen-Independent Prostate Cancer. *J Clin Oncol* 2004; **J Clin Oncol** 2004; 22:2522-2531
12. Konishi S, Hamacher KA, **Vallabhajosula S**, Kothari P, Bastidas D, Bander NH, Goldsmith SJ. Determination of Immunoreactive Fraction of Radiolabeled MAbs: What is an Appropriate Method?

13. **Vallabhajosula S**, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowski MI, Nanus DM, Bander NH, Goldsmith SJ. Pharmacokinetics and biodistribution of <sup>111</sup>In- and <sup>177</sup>Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of <sup>90</sup>Y-J591 radiation dosimetry based on <sup>111</sup>In or <sup>177</sup>Lu? J Nucl Med 2005;46:634-641
14. **Vallabhajosula S**, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, Nanus DM, Bander NH. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using <sup>90</sup>Y- and <sup>177</sup>Lu-labeled J591 antibodies specific for prostatespecific membrane antigen. J Nucl Med 2005;46: 850-858
15. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, **Vallabhajosula S**, Goldsmith SJ. Phase I Trial of <sup>177</sup>Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer. J Clin Oncol 2005;20;23(21): 4591-4601
16. David KA, Milowsky MI, Kostakoglu L, **Vallabhajosula S**, Goldsmith SJ, Nanus DM, Bander NH. Clinical utility of radiolabeled monoclonal antibodies in prostate cancer. Clinical Genitourinary Cancer. 4:249-56, 2006
17. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, **Vallabhajosula S**, Goldsmith SJ, Ross JS, and Bander NH. Vascular Targeted Therapy With Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid Tumors. J Clin Oncol 2007; 25:540-547.

## **Appendix- A**

### **DOTA-J591**

**Certificate of Analysis from Immunomedics, Inc.**



# CERTIFICATE OF ANALYSIS

**J591 IgG-DOTA**

**P/N: 73406, C/N: 0612012**

Assay	Specification*	Results
Potency	Report IgG-DOTA concentration and protein content.	7.5 mg/mL 10 mg/vial
Radiolabeling	Report Results	98.5% IgG-DOTA- <sup>111</sup> In
Radiochemical Purity by ITLC	Report Results	99.0% IgG-DOTA- <sup>111</sup> In
DOTA/IgG Ratio	Report results	3.4

Storage: 2-8 °C

Date of Manufacture: December 6, 2006

Date of Expiration: TBD

The above material meets all of the specifications.

*Df Shieh*

*12/13/06*


Ding Shieh

Date

Quality Control Director

*8 mg/mL  
x 1.3 mL/vial = 10.4 mg/vial  
161 vials = 1,674 mg  
from 97% of 200 mg vial of Ab  
~85% efficiency*

### Process Flow Chart for DOTA-Conjugation of J591 Antibody



Immunomedics <sup>®</sup> , Inc.	Shipping Request Form	Appendix A Document: M401 Revision: 12 Effective Date: MAY 20 2006
----------------------------------	-----------------------	---

Should be received by QA 48-hours prior to shipment. No Friday shipments.

Today's Date: 1/9/07	Date to be Shipped: 1/9/07
Shipping Address: Dr. Neil H. Bander Laboratory of Urologic Oncology Weill Medical College of Cornell University 1300 <del>BEE</del> York Avenue, E300 New York, NY 10021	
Telephone #: 212-746-5493	
Protocol #: N/A	Lot #: N/A
FDA on File: N/A	Investigator's Name: Neil H. Bander
Product to be Shipped: 161 24 1/9/07 <del>168</del> vials of J591 19G-DOA CN: 061202	
Initial Shipment? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Coded <input type="checkbox"/> Uncoded (Please Check)	
ITLC Strips Needed? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Approval Signatures and Date	
Requisitioner: R Myle 1/9/07	
Manager Approval: R Myle 1/9/07	
Regulatory Affairs Approval: [Signature] 1/9/07	
QA Approval: Ryeen 1/9/07	
Dispatched By: Jang Paults 1/9/07	

ORIGINAL COPY  
Confidential and Proprietary Property  
of Immunomedics, Inc.

**Temperature Recorder  
Activation Form**  
(For shipments from Immunomedics)Appendix A  
Document: Q408  
Revision: 5  
Effective Date: 10/30/04**Part I: To be completed by Immunomedics**Product Shipped: J591 IgG-DOTAStorage Condition of Product Shipped: ☒ 2-8°C ☐ <-20°C ☐ <-70°C ☐ AmbientPart Number: 73406 Control Number: 0612012Number of temperature recorder(s) in this shipment: 2 S/N: 3403628758

Time temperature recorder(s) activated and placed into package:

Time: 2:30 PM EST Date: 1/9/07Performed by: RY Date: 1/9/07

**NOTE: Please Complete the Part II and RETURN This Document and All the Temperature Recorders to Immunomedics, Inc., by Overnight Carrier.**

**Part II: Shipment Receipt, To be completed by the RECEIVER**Date Package Received: 1/10/07 Time Received: p.m. Received By: VNCondition of outside container: ☒ Good ☐ Damaged

If damaged, describe damage: \_\_\_\_\_

Performed By: Vince N. NAWARRD Date: 1/10/07

Time temperature recorder(s) removed from shipment container:

Time: 3 pm EST Date: 1/10/07Performed by: VN Date: 1/10/07

**Note: Once Shipment container is opened upon receipt, temperature recorder(s) & product must be promptly removed and properly stored at the specified temperature.**

**ORIGINAL**

COPY